Shares of Ventrus Biosciences Inc. jumped Monday after the company said a late-stage study shows its diltiazem cream is more effective than a placebo as a treatment for anal fissures.
Boston Globe: Business
Mon, 05/14/2012 - 11:54am
Shares of Ventrus Biosciences Inc. jumped Monday after the company said a late-stage study shows its diltiazem cream is more effective than a placebo as a treatment for anal fissures.